Key clinical point: The progressive death 1 inhibitor pembrolizumab, given with or without vismodegib, resulted in robust response rates in some patients with advanced basal cell carcinoma.
Major finding: The overall response rate was 38%, or 6 of 16 patients, with a 70% probability of 1-year progression-free survival and 94% probability of 1-year overall survival.
Study details: A nonrandomized, investigator-initiated study including 16 patients with advanced basal cell carcinoma.
Disclosures: Funding for the study was provided by Merck. Dr. Chang reported serving as a clinical investigator and advisory board member for studies sponsored by Genentech-Roche, Merck, Novartis, and Regeneron.
REPORTING FROM WCD2019